Evaluation of clinical effect of compound Shelong Capsule on urinary protein in membranous nephropathy

Shanxi Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•(1) Consistent with the clinical diagnosis of chronic nephritis and stage I-II pathological diagnosis of membranous nephropathy;
•(2) TCM syndrome differentiation belongs to the syndrome of mutual obstruction of dampness and stasis;
•(3)0.3g/24h= 24h urinary protein quantification <3.5g/24h;
•(4) Serum creatinine =176µmol/L, or glomerular filtration rate (GFR)= 60mL /(min·1.73m2);
•(5) Aged between 16 and 65, regardless of gender;
•(6) Acute aggravating factors such as infection, electrolyte disturbance, severe hypertension, hyperlipemia and hyperglycemia can be effectively controlled;
•(7) Those who voluntarily participate in the experiment and sign the informed consent.

•(1) Patients with serious primary diseases of the heart, brain, liver and hematopoietic system, type 1 diabetes, or other serious diseases affecting their survival;
•(2) 24-hour urine protein quantification =3.5g/24h or < 0.4g/24h;
•(3) serum creatinine =177µmol/L, or serum creatinine clearance (GFR)<60ml/(min·1.73m2);
•(4) pregnant or lactating women;
•(5) Persons with allergic constitution who have a history of drug allergy or are known to be allergic to the drug components in the test;
•(6) Those who are taking similar study drugs or antihypertensive drugs with protein-lowering effect or are currently taking hormone or immunosuppressive therapy;
•(7) mentally ill or legally disabled persons;
•(8) Those who have no fixed place to work and are easy to fall off;
•(9) Participants in another clinical drug trial.

发起方

Shanxi Hospital of Traditional Chinese Medicine